Pressmeddelanden

REG
PILA PHARMA PUBLISHES YEAR-END REPORT (1 JANUARY - 31 DECEMBER 2024) PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company's year-end report for the period January - December 2024. The report can be found on the Company's website: https...
PILA PHARMA INVITES TO H2 REPORT WEBINAR & INVESTOR Q&A PILA PHARMA AB (publ) (FN STO: PILA) hereby invites interested investors to participate in our scheduled H2 Report event in the coming week: ___________Stokk.io Online Webinar -...
REG MAR
PILA PHARMA ANNOUNCES PRECLINICAL PROOF-OF-CONCEPT ACHIEVED IN CARDIOVASCULAR DISEASE STUDY PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the completion of the study of the Research Group of Professor Dick Wågsäter, Uppsala University, Sweden (t...
PILA PHARMA ANNOUNCES NEW CHIEF FINANCIAL OFFICER (CFO) PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the appointment of Hampus Darrell as new CFO.
PILA PHARMA ANNOUNCES INITIATION OF STUDY IN PRECLINICAL RESEARCH COLLABORATION IN CARDIOVASCULAR DISEASE PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the initiation of the study associated to the co-sponsorship of the research collaboration with the Researc...
PILA PHARMA INVITES TO NORDIC INVESTOR MEETINGS PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") (FN STO: PILA) hereby invites you to participate in these upcoming Nordic investor events:
Visa fler pressmeddelanden

Rapporter

Datum Rubrik
Year-end report 2024
Interim report 1 January - 30 June 2024
Årsredovisning 2023

Video

Finansiell kalender

Årsredovisning Årsredovisning
Halvårsrapport 2025 Delårsrapport

Om PILA PHARMA

Prenumerera

Få löpande information från PILA PHARMA via e-post.

Handelsinformation

Kurs ()
Förändring ()
Marknad Nasdaq First North Growth Market Kortnamn PILA ISIN-kod SE0015988274 Certified Adviser Aqurat Fondkommission